Monday, December 12, 2011

AVI Biopharma Chops 28 Percent

Bothell-based AVI Biopharma, which develops RNA-based therapeutics for rare and infectious diseases, said late Friday that it has chopped its workforce by approximately 28 percent, as part of an effort to "streamline" the firm's infrastructure and lower overall expenses. The firm--which buried the announcement deep within a VP appointment announcement released late Friday--said it will focus its resources on rare and infectious diseases.